Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection.

ABSTRACT:

Introduction

Asunaprevir (ASV) is a potent, pangenotypic, twice-daily hepatitis C virus (HCV) NS3 inhibitor indicated for the treatment of chronic HCV infection.

Methods

A population pharmacokinetic (PPK) model was developed using pooled ASV concentration data from 1239 HCV-infected subjects who received ASV either as part of the DUAL regimen with daclatasvir or as part of the QUAD regimen with daclatasvir and peg-interferon/ribavirin.

Results

A two-compartment model with first-order elimination from the central compartment, an induction effect on clearance, and an absorption model consisted of zero-order release followed by first-order absorption adequately described ASV PK after oral administration. A typical value for ASV clearance (CL/F) was 50.8 L/h, increasing b

SUBMITTER: Zhu L 

PROVIDER: S-EPMC5986681 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature